Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the HorizonOn July 25, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that the European Medicines Agency’s CHMP has given a positive opinion for its TRYNGOLZA.

The drug is recommended as an add-on to diet for adults with genetically confirmed familial chylomicronemia syndrome. The disease causes very high triglyceride levels and increases the risk of severe pancreatitis. Management noted that this positive opinion is a step forward towards European Commission approval, which is expected by the end of 2025.

Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency

A scientist in a laboratory making a breakthrough discovery in biotechnology.

The drug has already been approved in the United States, and the phase 3 Balance study showed that TRYNGOLZA significantly reduced triglyceride levels and acute pancreatitis events.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) develops RNA-targeted medicines for serious diseases, including neurological, cardiovascular, and rare genetic disorders.

While we acknowledge the potential of IONS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IONS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.